In the context of NSCLC, T-DM1 was the first ADC to be tested, and it showed the best ORR and PFS in comparison to other HER2 drugs and/or conventional therapy and anti-EGFR TKIs; however, although promising short-term efficacy, the response duration was limited [37,38,39]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.